BioSpace News Archive

Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases recently announced its support of the Immune Deficiency Foundation Research Grant Program for the second year in a row.

Bruker Corporation announced it will report second quarter 2023 financial results before market opening on Thursday, August 3, 2023.

Zynerba Pharmaceuticals, Inc. announced that the new date for the adjourned 2023 Annual Meeting of Stockholders is August 11, 2023 at 9:00 a.m. EDT.

Truvian Health today presented results from a recent multi-site clinical study at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting demonstrating the ability of its benchtop blood testing platform to deliver central laboratory quality results simultaneously across a large panel of assays.

A new artificial intelligence model can predict people’s risk of multiple sclerosis years before diagnosis, potentially enabling quicker treatment, according to research revealed today at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo.

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.

23andMe Holding Co. announced that it will report financial results for the fiscal year 2024 first quarter after the market closes on Tuesday, August 8, 2023.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”) today announced that it will report results for the second quarter ended June 30, 2023, and provide an update on recent developments in its business after market close on Monday, August 7, 2023.

OPKO Health, Inc. plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 second quarter on Tuesday, August 8, after the market close.